Jan T Poolman

Summary

Affiliation: GlaxoSmithKline Biologicals
Country: Belgium

Publications

  1. ncbi Pneumococcal vaccine development
    Jan T Poolman
    R and D Bacterial Vaccine Programme, GlaxoSmithKline Biologicals, Rue de l Institut, 89 1330 Rixensart, Belgium
    Expert Rev Vaccines 3:597-604. 2004
  2. ncbi Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics
    Jan Poolman
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 27:3213-22. 2009
  3. ncbi Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay
    Jan T Poolman
    GlaxoSmithKline Biologicals, Rixensart 1330, Belgium
    Clin Vaccine Immunol 18:1108-17. 2011
  4. ncbi Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines
    Jan Poolman
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Expert Rev Vaccines 10:307-22. 2011
  5. ncbi Acellular pertussis vaccines and the role of pertactin and fimbriae
    Jan T Poolman
    Head of Bacterial Vaccines, R and D Bacterial Vaccine Program, GlaxoSmithKline Biologicals, Rixensart, Belgium
    Expert Rev Vaccines 6:47-56. 2007
  6. ncbi Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines
    Jan Poolman
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330 Rixensart, Belgium
    Clin Vaccine Immunol 18:327-36. 2011
  7. ncbi Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines
    Jan T Poolman
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, Rixensart B 1330, Belgium
    Clin Vaccine Immunol 17:134-42. 2010
  8. ncbi Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression
    Nathalie Devos
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Microbes Infect 14:979-88. 2012
  9. ncbi A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae
    Philippe DeNoel
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 29:5495-501. 2011
  10. ncbi Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines
    Philippe A Denoel
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Clin Vaccine Immunol 14:1362-9. 2007

Collaborators

Detail Information

Publications19

  1. ncbi Pneumococcal vaccine development
    Jan T Poolman
    R and D Bacterial Vaccine Programme, GlaxoSmithKline Biologicals, Rue de l Institut, 89 1330 Rixensart, Belgium
    Expert Rev Vaccines 3:597-604. 2004
    ..The burden of adult nonbacteremic pneumococcal pneumonia has remained high and efforts to develop improved adult pneumococcal vaccines have been initiated that include conjugates and pneumococcal proteins...
  2. ncbi Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics
    Jan Poolman
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 27:3213-22. 2009
    ..In contrast to the other vaccine serotypes, no protection could be demonstrated in the POET study against serotype 3 acute otitis media (AOM) following primary and booster vaccination with a multi-valent pneumococcal conjugate vaccine...
  3. ncbi Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay
    Jan T Poolman
    GlaxoSmithKline Biologicals, Rixensart 1330, Belgium
    Clin Vaccine Immunol 18:1108-17. 2011
    ..In conclusion, SBA results obtained using the MenA L10 3125 strain better reflected vaccine-induced immunity...
  4. ncbi Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines
    Jan Poolman
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Expert Rev Vaccines 10:307-22. 2011
    ..These data have implications for the development of new multivalent vaccines...
  5. ncbi Acellular pertussis vaccines and the role of pertactin and fimbriae
    Jan T Poolman
    Head of Bacterial Vaccines, R and D Bacterial Vaccine Program, GlaxoSmithKline Biologicals, Rixensart, Belgium
    Expert Rev Vaccines 6:47-56. 2007
    ..The available data, therefore, demonstrate that appropriately formulated acellular vaccines containing PT and PRN are the preferred option for pertussis immunization...
  6. ncbi Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines
    Jan Poolman
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330 Rixensart, Belgium
    Clin Vaccine Immunol 18:327-36. 2011
    ..In conclusion, these results suggest that the conjugation method can influence the functionality of the antibodies induced against the homologous serotype 19F and the cross-reactive serotype 19A of S. pneumoniae...
  7. ncbi Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines
    Jan T Poolman
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, Rixensart B 1330, Belgium
    Clin Vaccine Immunol 17:134-42. 2010
    ..In conclusion, we confirm that the 22F ELISA can be recommended as a reference method for the determination of antibodies against pneumococcal polysaccharides...
  8. ncbi Neisseria meningitidis serogroup B lipooligosaccharide genotyping reveals high prevalence of L2 strains in Spain and unexpected relationship with factor H-binding protein expression
    Nathalie Devos
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Microbes Infect 14:979-88. 2012
    ..Our findings suggest that, in addition to a genetic analysis, a multivalent approach may be necessary to estimate the effectiveness of a N. meningitidis serogroup B vaccine...
  9. ncbi A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae
    Philippe DeNoel
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Vaccine 29:5495-501. 2011
    ..In conclusion, AS02-adjuvanted PhtD-dPly vaccine protects against S. pneumoniae-induced pneumonia. It is probable that the protection is at least partially mediated by PhtD- and Ply-specific antibodies...
  10. ncbi Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines
    Philippe A Denoel
    GlaxoSmithKline Biologicals, Rue de l Institut 89, 1330 Rixensart, Belgium
    Clin Vaccine Immunol 14:1362-9. 2007
    ..In conclusion, in vitro and in vivo data as well as postmarketing vaccine effectiveness data attest to the ability of DTPa-based/Hib combination vaccines to effectively prevent Hib-induced disease in children...
  11. ncbi Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens
    Fabrice Godfroid
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330 Rixensart, Belgium
    Infect Immun 79:238-45. 2011
    ..Our findings, together with the serotype-independent occurrence of the Phts, designate this protein family as valid candidate antigens to be incorporated in protein-based pneumococcal vaccines...
  12. ncbi Transcriptional regulation, occurrence and putative role of the Pht family of Streptococcus pneumoniae
    Stéphane Rioux
    GSK Biologicals, Rixensart, Belgium
    Microbiology 157:336-48. 2011
    ..The data also showed that this protein family, and more particularly PhtD, is a promising candidate to be incorporated into pneumococcal vaccines...
  13. ncbi Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response
    V Weynants
    Research and Development, GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330 Rixensart, Belgium
    Infect Immun 77:2084-93. 2009
    ..In conclusion, a bivalent detoxified LOS OMV-based vaccine demonstrated the potential to afford a broad cross-protection against meningococcal disease...
  14. ncbi Meningococcal surface fibril (Msf) binds to activated vitronectin and inhibits the terminal complement pathway to increase serum resistance
    Natalie J Griffiths
    Schools of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK
    Mol Microbiol 82:1129-49. 2011
    ..The data imply that vitronectin binding may be an important strategy for the in vivo survival of Nm for which the bacterium has evolved redundant mechanisms...
  15. ncbi Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis
    Vincent E Weynants
    GlaxoSmithKline Biologicals, Rue de l Institut 89, B 1330 Rixensart, Belgium
    Infect Immun 75:5434-42. 2007
    ..With minor OMPs, this threshold is reached when more than one antigen is targeted, and this allows cross-protection...
  16. ncbi Preparation of polysaccharide-conjugate vaccines
    Carla C A M Peeters
    Laboratory for Vaccine Development and Immune Mechanisms, National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands
    Methods Mol Med 87:153-74. 2003
  17. ncbi Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae
    Laura A Novotny
    Columbus Children's Research Institute, Center for Microbial Pathogenesis, The Ohio State University College of Medicine and Public Health, 700 Children's Drive, W591, 43205, USA
    Vaccine 24:4804-11. 2006
    ..6% was shown against acute OM episodes caused by NTHI. These observations strongly support the chinchilla passive transfer-superinfection model as one that could predict clinical trials outcomes for vaccines to prevent NTHI-induced OM...
  18. ncbi Vaccine potential of the Neisseria meningitidis lactoferrin-binding proteins LbpA and LbpB
    Annika Pettersson
    Department of Molecular Microbiology, Institute of Biomembranes, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
    Vaccine 24:3545-57. 2006
    ..Our results show that both proteins are immunogenic and able to induce bactericidal antibodies, but that the cross-reactivity of these antibodies is limited...
  19. ncbi Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates
    Ron Dagan
    Pediatric Infectious Disease Unit, Soroka University Medical Center, PO Box 151, Beer Sheva 84101, Israel
    Expert Rev Vaccines 7:97-115. 2008
    ..These observations underline the need to carefully evaluate upcoming pediatric conjugate vaccines for possible interference effects on the coadministered antigens, with particular attention to hepatitis B and Hib-tetanus toxoid...